益生菌减少坦桑尼亚新生儿感染与死亡及预防产超广谱β-内酰胺酶细菌定植的随机对照试验方案
ProRIDE试验为在坦桑尼亚Haydom地区开展的大规模随机双盲安慰剂对照试验,计划招募2000名新生儿,出生后0-3天入组并接受益生菌或安慰剂4周,随访6个月。主要复合结局为6月龄时死亡和/或住院的患病率,旨在评估益生菌能否降低婴儿发病率与死亡率,并与减少产超广谱β-内酰胺酶肠杆菌科细菌(ESBL-E)定植和/或感染相关。
要点
- 益生菌可能减少婴儿肠道多重耐药菌定植,但证据有限。
- 该试验以6月龄死亡和/或住院为主要复合结局。
- 入组后干预4周,随访6个月并采集直肠拭子和粪便样本。
核心结论
- 益生菌可能通过改善肠道菌群组成降低坦桑尼亚新生儿发病率和死亡率,结果可能影响非洲及国际未来治疗指南。
主要发现
- 研究尚未报告结果;方案指出坦桑尼亚儿童ESBL-E感染死亡率高且肠道ESBL-E定植率很高,而益生菌减少婴儿ESBL-E携带的数据有限。
关键数值与推荐
- 主要复合结局为6月龄时死亡和/或住院的患病率。
- 随访期间进行三次访视,收集临床和人口学信息以及直肠拭子和粪便样本用于实验室分析。
临床怎么用
- 若试验证实益生菌有效,可能为非洲及国际新生儿感染预防和治疗指南提供依据。
局限性
- 本文为研究方案,尚无结果数据;益生菌减少婴儿ESBL-E定植的证据目前有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBL-E) has emerged as an urgent global health threat and is by the World Health Organization ranked as priority 1 among pathogens in need of new treatment. Studies have shown high mortality in Tanzanian children with ESBL-E infections. Gut colonization of ESBL-E, which is a potential risk factor of ESBL-E infections, is reported to be very high among children in Tanzania. Probiotics may potentially reduce gut colonization of multidrug-resistant bacteria. However, there is limited data on whether probiotics may reduce ESBL-E carriage in infants. The ProRIDE Trial aims to evaluate whether the use of probiotics can reduce morbidity and mortality among infants in Haydom, Tanzania, and whether this effect is associated with a reduction in ESBL-E colonization and/or infections. METHODS/DESIGN: This large randomized double-blinded placebo-controlled trial aims to recruit 2000 newborn infants at Haydom Lutheran Hospital and the surrounding area in the period of November 2020 to November 2021. Participants will be enrolled from days 0 to 3 after birth and randomized to receive probiotics or placebo for 4 weeks. Participants will be followed-up for 6 months, during which three visits will be made to collect clinical and demographic information, as well as rectal swabs and fecal samples which will be subjected to laboratory analysis. The primary composite outcome is the prevalence of death and/or hospitalization at 6 months of age. DISCUSSION: As the use of probiotics may give a more favorable gut composition, and thereby improve health and reduce morbidity and mortality, the results may have implications for future therapy guidelines in Africa and internationally. TRIAL REGISTRATION: ClinicalTrials.gov NCT04172012. Registered on November 21, 2019.
引用
- Kuwelker K, Langeland N, Löhr IH, et al. Use of probiotics to reduce infections and death and prevent colonization with extended-spectrum beta-lactamase (ESBL)-producing bacteria among newborn infants in Tanzania (ProRIDE Trial): study protocol for a randomized controlled clinical trial. Trials. 2021. PMID: 33926519. doi:10.1186/s13063-021-05251-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。